Type 1 diabetes market to reach $9.9 billion in 7MM by 2033

2 January 2025

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033.

The sector will be driven by the anticipated introduction of several late-stage pipeline products, including multiple immunomodulatory agents, during the forecast period, according to pharma analytics company GlobalData.

GlobalData’s latest report, “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, reveals that the USA is the largest T1D market in the 7MM, accounting for 80.4% of global sales in 2023 ($2.2 billion), and is expected to gain further market share during the forecast period, accounting for 91.6% of 7MM T1D sales by 2033 ($9.0 billion).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK